Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives.
IBD
adalimumab
biological
histology
infliximab
vedolizumab
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
30 Aug 2021
30 Aug 2021
Historique:
received:
09
08
2021
revised:
26
08
2021
accepted:
27
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Chronic inflammatory bowel diseases (IBDs) are gaining increasing attention, both because they can severely reduce the quantity and quality of life, and because the advent of monoclonal antibodies has profoundly changed the natural history of these diseases. In recent years, the concept of mucosal healing has assumed a certain importance, and there are more and more clinical and pharmacological trials that consider this parameter among their endpoints, so much so that it may soon be included among the desirable clinical outcomes of patients with IBD. We performed a literature review of the Pubmed, Medline, and Web of Science (WoS) databases. We selected 88 articles and then removed 6 duplicates; the final sample after accurate application of the inclusion criteria numbered 73 articles, with a level of evidence rating of three or four, according to Oxfords Evidence-based medicine. Our aim was to study the histological impact of monoclonal antibody therapies on mucosal healing, taking into consideration the few studies present in the literature. To perform this review, we compared studies that examined patients with Crohn's disease (CD) and/or ulcerative colitis (UC) undergoing monoclonal therapy versus patients undergoing other non-biological therapies (PICO statements). We try to delineate how monoclonal antibodies have changed the natural history of IBD, acting at the microscopic level, and we believe that a careful analysis of the histopathology and the definition of the objective criteria for "Mucosa Healing" should enable this concept to be included among the clinical endpoints of patients affected by IBD, thus contributing to a better therapeutic management of these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic inflammatory bowel diseases (IBDs) are gaining increasing attention, both because they can severely reduce the quantity and quality of life, and because the advent of monoclonal antibodies has profoundly changed the natural history of these diseases. In recent years, the concept of mucosal healing has assumed a certain importance, and there are more and more clinical and pharmacological trials that consider this parameter among their endpoints, so much so that it may soon be included among the desirable clinical outcomes of patients with IBD.
METHODS
METHODS
We performed a literature review of the Pubmed, Medline, and Web of Science (WoS) databases.
RESULTS
RESULTS
We selected 88 articles and then removed 6 duplicates; the final sample after accurate application of the inclusion criteria numbered 73 articles, with a level of evidence rating of three or four, according to Oxfords Evidence-based medicine. Our aim was to study the histological impact of monoclonal antibody therapies on mucosal healing, taking into consideration the few studies present in the literature. To perform this review, we compared studies that examined patients with Crohn's disease (CD) and/or ulcerative colitis (UC) undergoing monoclonal therapy versus patients undergoing other non-biological therapies (PICO statements).
CONCLUSIONS
CONCLUSIONS
We try to delineate how monoclonal antibodies have changed the natural history of IBD, acting at the microscopic level, and we believe that a careful analysis of the histopathology and the definition of the objective criteria for "Mucosa Healing" should enable this concept to be included among the clinical endpoints of patients affected by IBD, thus contributing to a better therapeutic management of these patients.
Identifiants
pubmed: 34573912
pii: diagnostics11091570
doi: 10.3390/diagnostics11091570
pmc: PMC8470623
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Aliment Pharmacol Ther. 2016 Feb;43(3):317-33
pubmed: 26607562
World J Gastroenterol. 2013 Nov 21;19(43):7552-60
pubmed: 24282345
Dig Liver Dis. 2007 Sep;39(9):811-7
pubmed: 17652038
Aliment Pharmacol Ther. 2019 Apr;49(8):1026-1039
pubmed: 30854708
F1000Res. 2019 Jul 29;8:
pubmed: 31448080
Dig Dis. 2016;34(1-2):175-9
pubmed: 26982457
Expert Rev Gastroenterol Hepatol. 2020 May;14(5):335-345
pubmed: 32315209
Gastroenterology. 2020 Dec;159(6):2052-2064
pubmed: 32853634
J Gastrointestin Liver Dis. 2010 Jun;19(2):147-53
pubmed: 20593047
World J Gastroenterol. 2018 Dec 21;24(47):5322-5330
pubmed: 30598577
Aliment Pharmacol Ther. 2018 Jan;47(2):162-175
pubmed: 29205406
Gastroenterology. 2019 Oct;157(4):1019-1031.e7
pubmed: 31279870
Gut. 1983 Jun;24(6):519-24
pubmed: 6852632
Gut. 2017 Jan;66(1):43-49
pubmed: 26464414
Clin Gastroenterol Hepatol. 2020 Dec 15;:
pubmed: 33338657
Gastroenterol Hepatol (N Y). 2012 Jan;8(1):29-38
pubmed: 22347830
Tech Coloproctol. 2007 Jun;11(2):91-6
pubmed: 17510748
Gut. 2018 Jan;67(1):43-52
pubmed: 27802155
Therap Adv Gastroenterol. 2020 Aug 25;13:1756284820941179
pubmed: 32922513
J Clin Gastroenterol. 2013 Mar;47(3):212-21
pubmed: 23340060
Gut. 2020 Jun;69(6):1053-1063
pubmed: 31506328
Trends Immunol. 2019 Jul;40(7):635-647
pubmed: 31160208
J Crohns Colitis. 2016 Aug;10(8):989-97
pubmed: 26896086
J Crohns Colitis. 2019 Jul 25;13(7):846-855
pubmed: 30541015
Mayo Clin Proc. 2019 Jul;94(7):1357-1373
pubmed: 31272578
Lancet. 2007 May 12;369(9573):1627-40
pubmed: 17499605
Gastroenterology. 2001 Jan;120(1):13-20
pubmed: 11208709
Gut Liver. 2017 Jul 15;11(4):455-463
pubmed: 28486793
Folia Histochem Cytobiol. 2016;54(2):75-80
pubmed: 27270504
Inflamm Bowel Dis. 2009 Sep;15(9):1295-301
pubmed: 19340881
Inflamm Bowel Dis. 2011 Apr;17(4):947-53
pubmed: 20860048
Digestion. 2021;102(4):534-545
pubmed: 32739919
Gut. 1991 Dec;32(12):1514-20
pubmed: 1773958
Eur J Gastroenterol Hepatol. 2012 Jul;24(7):762-9
pubmed: 22517240
Curr Drug Targets. 2012 Sep 1;13(10):1294-9
pubmed: 22664087
PLoS One. 2016 Oct 24;11(10):e0165435
pubmed: 27776175
Dis Mon. 2019 Dec;65(12):100851
pubmed: 30837080
Expert Opin Biol Ther. 2020 Nov;20(11):1321-1329
pubmed: 32662683
Gastrointest Endosc. 2015 Aug;82(2):246-55
pubmed: 26005012
Curr Pharm Des. 2014;20(7):1082-96
pubmed: 23782147
J Crohns Colitis. 2020 May 21;14(4):508-524
pubmed: 31630153
Dtsch Arztebl Int. 2020 Aug 17;117(33-34):564-574
pubmed: 33148393
Aliment Pharmacol Ther. 2017 May;45(10):1291-1302
pubmed: 28326566
Inflamm Bowel Dis. 2016 Aug;22(8):1859-69
pubmed: 27206015
Inflamm Bowel Dis. 2019 May 16;25(Suppl 2):S5-S12
pubmed: 31095706
Gastroenterology. 1999 Jan;116(1):22-8
pubmed: 9869598
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
J Crohns Colitis. 2017 Dec 4;11(12):1440-1448
pubmed: 28961760
Prim Care. 2017 Dec;44(4):673-692
pubmed: 29132528
Scand J Gastroenterol. 1994 Apr;29(4):318-32
pubmed: 8047806
Gastroenterology. 1999 May;116(5):1029-34
pubmed: 10220494
Mediators Inflamm. 2015;2015:793764
pubmed: 25873771
Annu Rev Immunol. 2017 Apr 26;35:119-147
pubmed: 28125357
J Crohns Colitis. 2019 Aug 14;13(8):970-975
pubmed: 30698684
Front Immunol. 2018 May 30;9:1171
pubmed: 29899742
Cell Rep. 2020 Jul 7;32(1):107857
pubmed: 32640223
Curr Drug Targets. 2011 Sep;12(10):1417-23
pubmed: 21466490
Mucosal Immunol. 2014 Jul;7(4):905-15
pubmed: 24345805
Inflamm Bowel Dis. 2020 May 12;26(6):961-969
pubmed: 31587036
Dig Liver Dis. 2013 Dec;45(12):969-77
pubmed: 23932331
Gastroenterology. 2019 Oct;157(4):997-1006.e6
pubmed: 31175865
Scand J Gastroenterol. 2015 Jan;50(1):43-52
pubmed: 25523555
Gut. 2012 Nov;61(11):1619-35
pubmed: 22842618
Gut. 2000 Sep;47(3):404-9
pubmed: 10940279
Gastroenterology. 2019 Oct;157(4):1007-1018.e7
pubmed: 31279871
Drugs. 2017 Feb;77(2):159-173
pubmed: 28078646
J Gastroenterol Hepatol. 2019 Dec;34(12):2118-2125
pubmed: 31039275
Gastroenterology. 2007 Aug;133(2):412-22
pubmed: 17681162
Histopathology. 2014 Feb;64(3):317-35
pubmed: 24266813
Aliment Pharmacol Ther. 2020 Jun;51(12):1373-1383
pubmed: 32383166
PLoS One. 2014 Oct 20;9(10):e110797
pubmed: 25330148
Adv Clin Chem. 2013;59:101-23
pubmed: 23461134
Dig Dis. 2016;34(1-2):160-4
pubmed: 26982170
World J Gastroenterol. 2015 Aug 7;21(29):8804-10
pubmed: 26269669
United European Gastroenterol J. 2019 Dec;7(10):1285-1303
pubmed: 31839954